ReviewNanomaterials (Basel, Switzerland)2019
Clinical Trials of Thermosensitive Nanomaterials: An Overview.
Review in Nanomaterials (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cancer therapy with iron oxide nanoparticles: Agents of thermal and immune therapies.Advanced drug delivery reviews · 2020Pooled it
- Hydrophilic and Lipophilic Carbon Dots Impart Thermosensitivity to Doxorubicin Loaded Phospholipid Liposomes.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Synthetic Biology and Biomaterials Strategies to Deceive the Tumor Microenvironment in CAR-T Immunotherapy.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- Oxygen Sensitive Drug Release Using Hemoglobin Microbubbles: A New Approach to Targeting Hypoxia in Ultrasound-Mediated Drug Delivery.International journal of pharmaceutics · 2025Article
- Applications and Efficacy of Iron Oxide Nanoparticles in the Treatment of Brain Tumors.Pharmaceutics · 2025Review
- Drug Release via Ultrasound-Activated Nanocarriers for Cancer Treatment: A Review.Pharmaceutics · 2024Review
- Magnetic Hyperthermia in Glioblastoma Multiforme Treatment.International journal of molecular sciences · 2024Review
- Gelatin-based biomaterials and gelatin as an additive for chronic wound repair.Frontiers in pharmacology · 2024Review
- Recent advances in nanoformulation-based delivery for cancer immunotherapy.Nanomedicine (London, England) · 2024Review
- Design of multi-modal antenna arrays for microwave hyperthermia and 1H/1⁹F MRI monitoring of drug release.PloS one · 2024Article
- The Evolution and Recent Trends in Acoustic Targeting of Encapsulated Drugs to Solid Tumors: Strategies beyond Sonoporation.Pharmaceutics · 2023Review
- Pharmacokinetic behaviors of soft nanoparticulate formulations of chemotherapeutics.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2023Review
- Nanoparticles: Taking a Unique Position in Medicine.Nanomaterials (Basel, Switzerland) · 2023Review
- Liposomes for Tumor Targeted Therapy: A Review.International journal of molecular sciences · 2023Review
- Gelatin-based anticancer drug delivery nanosystems: A mini review.Frontiers in bioengineering and biotechnology · 2023Review
- Harnessing Ultrasound for Targeting Drug Delivery to the Brain and Breaching the Blood-Brain Tumour Barrier.Pharmaceutics · 2022Review
- Magnetic Self-Healing Composites: Synthesis and Applications.Molecules (Basel, Switzerland) · 2022Review
- Review
- Ultrasound and nanomaterial: an efficient pair to fight cancer.Journal of nanobiotechnology · 2022Review
- Iron-Gold Nanoflowers: A Promising Tool for Multimodal Imaging and Hyperthermia Therapy.Pharmaceutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Currently, we are facing increasing demand to develop efficient systems for the detection and treatment of diseases that can realistically improve distinct aspects of healthcare in our society. Sensitive nanomaterials that respond to environmental stimuli can play an important role in this task. In this manuscript, we review the clinical trials carried out to date on thermosensitive nanomaterials, including all those clinical trials in hybrid nanomaterials that respond to other stimuli (e.g., magnetic, infrared radiation, and ultrasound). Specifically, we discuss their use in diagnosis and treatment of different diseases. At present, none of the existing trials focused on diagnosis take advantage of the thermosensitive characteristics of these nanoparticles. Indeed, almost all clinical trials consulted explore the use of Ferumoxytol as a current imaging test enhancer. However, the thermal property is being further exploited in the field of disease treatment, especially for the delivery of antitumor drugs. In this regard, ThermoDox®, based on lysolipid thermally sensitive liposome technology to encapsulate doxorubicin (DOX), is the flagship drug. In this review, we have evidenced the discrepancy existing between the number of published papers in thermosensitive nanomaterials and their clinical use, which could be due to the relative novelty of this area of research; more time is needed to validate it through clinical trials. We have no doubt that in the coming years there will be an explosion of clinical trials related to thermosensitive nanomaterials that will surely help to improve current treatments and, above all, will impact on patients' quality of life and life expectancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.